Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Duobrii (halobetasol/tazarotene) and Tremfya (guselkumab) are both used to treat plaque psoriasis, but they work in different ways and are used for different severities of the condition. Duobrii is a topical lotion that combines a corticosteroid and a retinoid to reduce inflammation and alter skin cell growth. It's applied once daily and is only available as a brand-name medication. On the other hand, Tremfya is an injection that targets a specific protein interleukin-23 (IL-23) to lower inflammation and is used for moderate-to-severe plaque psoriasis, ulcerative colitis, and psoriatic arthritis. Tremfya is also a brand-name medication and is injected every 8 weeks after initial doses. Duobrii can cause skin sensitivity to the sun and isn't recommended for long-term use, while Tremfya can raise the risk of infections and requires monitoring for tuberculosis. Additionally, Duobrii is not safe for use during pregnancy, whereas the safety of Tremfya during pregnancy is not well established.
Duobrii (halobetasol / tazarotene)
Tremfya (guselkumab)
Duobrii (halobetasol / tazarotene)
Tremfya (guselkumab)
Summary of Duobrii vs. Tremfya
Summary for Corticosteroid / Retinoid
Prescription only
Duobrii is a combination medication that contains halobetasol (a corticosteroid) and tazarotene (a retinoid). It's a prescription topical lotion that's FDA-approved to treat plaque psoriasis in adults. The directions for using the medication are to apply a thin amount over the affected area(s) of skin once per day. But avoid putting on the face, groin, and underarms. Side effects aren't common, but can include skin rash and pain at the site of application. Duobrii is brand name only and not available as a generic.
Summary for Interleukin antagonist
Prescription only
Tremfya (guselkumab) is an injection for adults with certain inflammatory conditions. It helps treat plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease. Tremfya (guselkumab) is a monoclonal antibody known as an interleukin antagonist. It calms your immune system to lower inflammation. The dosing schedule is every 1 or 2 months, depending on your condition and how far along you are in treatment. Side effects are upper respiratory infections, headache, and injection site reactions. There's also a risk of other infections and liver problems as long-term side effects.